Week in Review: Reprocessed catheters recalled | New payment model almost here | 3-year SMART data | Hypertension drug approved

Stryker Sustainability Solutions is recalling more than 8,000 reprocessed medical devices. This is a Class II recall, according to the FDA, and these devices should no longer be used to treat patients.

Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

Vivek Reddy, MD, spoke to Cardiovascular Business about some of the biggest trends in electrophysiology today.

Late-breaking data out of EuroPCR focused on 420 patients treated with Boston Scientific's new coronary IVL catheter. Overall, the device was found to be both safe and effective for patients with severe CAD.

Devi Nair, MD, reviewed some of the rare complications clinicians are seeing with PFA.

Boston Scientific has invested heavily in Georgia-based MiRus, a rising name in the competitive TAVR landscape.

The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.